Formulations

Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More


  • No Image
    Aditya Birla Chemicals Ltd

    Aditya Birla Chemicals (India) (ABCIL) is a unit of the Aditya Birla Group. Commissioned in 1984 with an initial caustic soda capacity of 33,000 tpa, the company has since grown

  • No Image
    Advanced Enzymes Technologies Ltd

    AETL, established in 1989, manufactures and markets enzyme products. The company has developed a portfolio of over 400 proprietary enzyme products from 55 enzymes. It is the lar